A Phase 3 interventional study of Aliskiren/amlodipine 300/10 mg tablet and Amlodipine 10 mg capsule in Moderate to Severe Hypertension, sponsored by Novartis. Completed at 6 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-12.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 228 studies in Hypertension by Novartis — 5 open to participants now, 6 under way, none of them phase 3. Hypertension · Novartis.
Among the 228 studies in Hypertension by Novartis, this one is the 80th largest by enrollment of the 223 interventional ones that give a count, is one of 17 that started in 2009, is one of 108 in phase 3, and was the 160th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →5 of the 228 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United Arab Emirates
Ages 18–99
Novartis Pharmaceuticals · Sites in Japan
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Japan, Singapore
Ages 18+
Novartis Pharmaceuticals
Ages 18+
By country, each count listing its studies:
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
228 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 31 · Phase 3 109 · Phase 4 67
First in 1989; this study’s year is marked. 17 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 485 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 300 across the 223 interventional studies, 813 across the 4 observational. Of the 219 that completed or were terminated, 88 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
4 of the studies in Hypertension by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07644364Novartis PharmaceuticalsHJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension | 2026-12-25 |
| NCT07610278Novartis PharmaceuticalsA Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | 2027-04-28 |
| NCT07465666Novartis PharmaceuticalsA Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates | 2027-08-31 |
| NCT07940647Novartis PharmaceuticalsA Safety and Tolerability Study of HJB647 in Adult Participants With Uncontrolled Hypertension | 2027-11-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 228 studies in Hypertension by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare the blood pressure (BP) lowering effect of the combination of aliskiren/amlodipine 300/10 mg versus amlodipine 10 mg monotherapy in patients with moderate to severe hypertension by testing the hypothesis that the combination of aliskiren/amlodipine produces a superior reduction from baseline in mean sitting systolic blood pressure (msSBP) after 8 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg.
Drug: Aliskiren/amlodipine 300/10 mg tablet
Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg.
Drug: Amlodipine 10 mg capsule
Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
Mean Sitting Systolic Blood Pressure (msSBP)
Change in mean sitting systolic blood pressure (msSBP) from baseline to end of study (Week 8)
Time frame: Baseline to end of study (Week 8)
Mean Sitting Diastolic Blood Pressure (msDBP)
Change in mean sitting diastolic blood pressure (msDBP) from baseline to end of study (Week 8)
Time frame: Baseline to end of study (Week 8)
Systolic Blood Pressure Response
Percentage of patients achieving a mean sitting systolic blood pressure response (msSBP \< 140 mmHg or a reduction =\> 20 mmHg from the baseline) from baseline to end of study (Week 8)
Time frame: Baseline to end of study (Week 8)
Diastolic Blood Pressure Response
Percentage of patients achieving a mean sitting diastolic blood pressure response (msDBP \< 90 mmHg or a reduction ≥ 10 mmHg from the baseline) from baseline to end of study (Week 8)
Time frame: Baseline to end of study (Week 8)
Blood Pressure Control
Percentage of patients achieving blood pressure control (msSBP \< 140 mm Hg and msDBP \< 90 mm Hg) at end of study
Time frame: End of study (Week 8)
| Milestone | Aliskiren/Amlodipine 300/10 mg Tablet | Amlodipine 10 mg Capsule |
|---|---|---|
| Started | 244 | 241 |
| Completed | 224 | 209 |
| Not completed | 20 | 32 |
| Withdrew: Adverse event | 7 | 16 |
| Withdrew: Abnormal test procedure result(s) | 0 | 1 |
| Withdrew: Subject withdrew consent | 2 | 4 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Administrative problems | 9 | 9 |
| Withdrew: Misrandomized | 1 | 0 |
| Withdrew: Protocol deviation | 0 | 1 |
Change in mean sitting systolic blood pressure (msSBP) from baseline to end of study (Week 8)
| mm Hg | Aliskiren/Amlodipine 300/10 mg Tablet | Amlodipine 10 mg Capsule |
|---|---|---|
| Mean Sitting Systolic Blood Pressure (msSBP) | -37.72 ± 0.937 | -30.63 ± 0.941 |
Change in mean sitting diastolic blood pressure (msDBP) from baseline to end of study (Week 8)
| mm Hg | Aliskiren/Amlodipine 300/10 mg Tablet | Amlodipine 10 mg Capsule |
|---|---|---|
| Mean Sitting Diastolic Blood Pressure (msDBP) | -16.10 ± 0.557 | -12.27 ± 0.559 |
Percentage of patients achieving a mean sitting systolic blood pressure response (msSBP \< 140 mmHg or a reduction =\> 20 mmHg from the baseline) from baseline to end of study (Week 8)
| Percentage of participants | Aliskiren/Amlodipine 300/10 mg Tablet | Amlodipine 10 mg Capsule |
|---|---|---|
| Systolic Blood Pressure Response | 88.8 | 79.1 |
Percentage of patients achieving a mean sitting diastolic blood pressure response (msDBP \< 90 mmHg or a reduction ≥ 10 mmHg from the baseline) from baseline to end of study (Week 8)
| Percentage of participants | Aliskiren/Amlodipine 300/10 mg Tablet | Amlodipine 10 mg Capsule |
|---|---|---|
| Diastolic Blood Pressure Response | 92.7 | 86.5 |
Percentage of patients achieving blood pressure control (msSBP \< 140 mm Hg and msDBP \< 90 mm Hg) at end of study
| Percentage of participants | Aliskiren/Amlodipine 300/10 mg Tablet | Amlodipine 10 mg Capsule |
|---|---|---|
| Blood Pressure Control | 67.0 | 49.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aliskiren/Amlodipine 300/10 mg Tablet | — | 0/243 (0%) | 41/243 (16.9%) |
| Amlodipine 10 mg Capsule | — | 3/241 (1.2%) | 56/241 (23.2%) |
| Event | Aliskiren/Amlodipine 300/10 mg Tablet | Amlodipine 10 mg Capsule |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/243 | 1/241 |
| Myocardial infarctionCardiac disorders | 0/243 | 1/241 |
| Cerebral infarctionNervous system disorders | 0/243 | 1/241 |
| AdenomyosisReproductive system and breast disorders | 0/243 | 1/241 |
| Dysfunctional uterine bleedingReproductive system and breast disorders | 0/243 | 1/241 |
| Event | Aliskiren/Amlodipine 300/10 mg Tablet | Amlodipine 10 mg Capsule |
|---|---|---|
| Oedema peripheralGeneral disorders | 35/243 | 44/241 |
| HeadacheNervous system disorders | 8/243 | 13/241 |
| Age Continuous(years) | Aliskiren/Amlodipine 300/10 mg Tablet | Amlodipine 10 mg Capsule | Total |
|---|---|---|---|
| Mean | 59 ± 10.38 | 59 ± 10.82 | 59 ± 10.60 |
| Sex: Female, Male(Participants) | Aliskiren/Amlodipine 300/10 mg Tablet | Amlodipine 10 mg Capsule | Total |
|---|---|---|---|
| Female | 136 | 139 | 275 |
| Male | 108 | 102 | 210 |
The record gives a start of Jan 2009, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.